(Q37703200)

22 August 2017

1 reference

title

Tadalafil: in pulmonary arterial hypertension (English)

1 reference

Katherine A Lyseng-Williamson

22 August 2017

author

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

22 August 2017

Jamie D Croxtall

1

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

479-488

1 reference

Evaluation and management of the patient with pulmonary arterial hypertension

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11204580-000000000-00000

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11204580-000000000-00000

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11204580-000000000-00000

Phosphodiesterase 11 (PDE11): is it a player in human testicular function?

21 January 2018

1 reference

12 December 2020

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

12 December 2020

1 reference

12 December 2020

Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension

1 reference

12 December 2020

Pulmonary Arterial Hypertension

1 reference

12 December 2020

High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors

1 reference

12 December 2020

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension

1 reference

12 December 2020

Drug treatment of pulmonary arterial hypertension: current and future agents

1 reference

12 December 2020

Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension

1 reference

12 December 2020

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

12 December 2020

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

1 reference

12 December 2020

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

1 reference

12 December 2020

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

1 reference

12 December 2020

Pulmonary arterial hypertension in France: results from a national registry

1 reference

12 December 2020

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

1 reference

12 December 2020

An epidemiological study of pulmonary arterial hypertension.

1 reference

12 December 2020

Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland

1 reference

12 December 2020

10.2165/11204580-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1045345116

0 references

1 reference